NEW YORK – Resolution Biosciences said Monday that it has entered an agreement with Laboratory Corporation of America to commercialize its Resolution ctDx Lung test.
LabCorp plans to launch the test in the first half of 2020 and will be its exclusive provider with Resolution performing the assay as a laboratory-developed test out of its CLIA facility.
The test uses next-generation sequencing to look for actionable mutations cell-free DNA from non-small cell lung cancer patients.